Gaucher disease and the clinical experience with substrate reduction therapy

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Gaucher disease is a genetic disorder caused by glucocerebroside accumulation due to enzyme defects.
• Type I Gaucher disease, the non-neuronopathic form, presents with organomegaly, anemia, and skeletal issues.
• Current enzyme replacement therapy is intravenous, costly, and cannot cross the blood-brain barrier.

Purpose of the Study:

• To evaluate the safety and efficacy of N-butyldeoxynojirimycin (OGT 918) as an oral substrate reduction therapy for Gaucher disease type I.
• To assess OGT 918 in adult patients naive to enzyme therapy and those already on enzyme replacement therapy.
• To compare the therapeutic outcomes of OGT 918 with traditional enzyme replacement therapy.

Main Methods:

• Long-term data from a seminal clinical trial involving adult patients with Gaucher disease type I.
• Administration of OGT 918 at doses of 100 mg three times daily and 50 mg three times daily.
• Evaluation of safety, efficacy, and side effects, including diarrhea, weight loss, tremor, and neuropathy.

Main Results:

• OGT 918 demonstrated safety and efficacy in treatment-naive adult patients with Gaucher disease type I.
• Dose dependency was observed, with 50 mg three times daily showing effects.
• Patients on enzyme therapy switched to or combined with OGT 918 showed no disease parameter deterioration, but experienced similar side effects.
• Side effects were generally reversible with dose adjustment.

Conclusions:

• N-butyldeoxynojirimycin (OGT 918) represents a promising oral therapeutic option for Gaucher disease type I.
• It is suitable for patients unwilling or unable to receive enzyme replacement therapy, provided they tolerate side effects.
• While efficacy may be less dramatic than enzyme therapy, long-term outcomes could be comparable.
• Patients with very mild disease manifestations may not be ideal candidates due to side effects and limited long-term data.